- Public Comps
- TempraMed Technologies
TempraMed Technologies Valuation Multiples
Discover revenue and EBITDA valuation multiples for TempraMed Technologies and similar public comparables like Carelabs, ContextVision, Doctor Care Anywhere, Jin Medical International and more.
TempraMed Technologies Overview
About TempraMed Technologies
TempraMed Technologies Ltd develops patent-protected solutions for managing and protecting temperature-sensitive medications. Its product range includes VIVI Cap for insulin pens and VIVI Epi for epinephrine injectors, which are distributed through pharmacy and retail networks globally. TempraMed generates the majority of its revenue from the sales of these devices, serving patients, healthcare providers, and pharmacy systems through operations in Southeast Asia, Europe, and Central America. The company enhances its reach by forming partnerships in the healthcare sector to broaden its access and drive usage in various geographic markets.
Founded
2023
HQ

Employees
10
Website
Financials (FY)
EV
$28M
Valuation Multiples
Start free trialTempraMed Technologies Financials
TempraMed Technologies reported last fiscal year revenue of $2M and negative EBITDA of ($18M).
In the same fiscal year, TempraMed Technologies generated $896K in gross profit, ($18M) in EBITDA losses, and had net loss of ($18M).
TempraMed Technologies P&L
In the most recent fiscal year, TempraMed Technologies reported revenue of $2M and EBITDA of ($18M).
TempraMed Technologies is unprofitable as of last fiscal year, with gross margin of 49%, EBITDA margin of (957%), and net margin of (987%).
Financial data powered by Morningstar, Inc.
TempraMed Technologies Stock Performance
TempraMed Technologies has current market cap of $27M, and enterprise value of $28M.
TempraMed Technologies' stock price is $0.34.
TempraMed Technologies has an EPS (earnings per share) of $-0.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28M | $27M | -0.2% | - | - | - | $-0.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTempraMed Technologies Valuation Multiples
TempraMed Technologies trades at 15.2x EV/Revenue multiple, and (1.6x) EV/EBITDA.
TempraMed Technologies Financial Valuation Multiples
As of August 14, 2026, TempraMed Technologies has market cap of $27M and EV of $28M.
TempraMed Technologies has a P/E ratio of (1.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TempraMed Technologies Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


TempraMed Technologies Margins & Growth Rates
In the most recent fiscal year, TempraMed Technologies reported gross margin of 49%, EBITDA margin of (957%), and net margin of (987%).
TempraMed Technologies Margins
TempraMed Technologies Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
TempraMed Technologies Operational KPIs
TempraMed Technologies' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
TempraMed Technologies Competitors
TempraMed Technologies competitors include Carelabs, ContextVision, Doctor Care Anywhere, Jin Medical International, Cambridge Cognition, Rockwell Medical, NextPlat, Healixa, CareView Communications and Prolight Diagnostics.
Most TempraMed Technologies public comparables operate across Medical Supplies, Healthcare Software, B2B SaaS, Vertical SaaS and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.0x | - | 0.1x | - | |||
| 1.9x | 1.7x | 28.4x | 9.2x | |||
| 0.6x | 0.6x | 5.4x | 4.8x | |||
| 0.8x | - | 17.0x | - | |||
| 1.9x | 1.6x | (26.5x) | (54.4x) | |||
| 0.3x | 0.3x | (10.0x) | 16.6x | |||
| 0.2x | 0.3x | (1.4x) | - | |||
| - | - | - | - | |||
This data is available for Pro users. Sign up to see all TempraMed Technologies competitors and their valuation data. Start Free Trial | ||||||
TempraMed Technologies VC Funding History
Before going public, TempraMed Technologies raised $5M in total equity funding, across 1 round.
TempraMed Technologies Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TempraMed Technologies
| When was TempraMed Technologies founded? | TempraMed Technologies was founded in 2023. |
| Where is TempraMed Technologies headquartered? | TempraMed Technologies is headquartered in Canada. |
| How many employees does TempraMed Technologies have? | As of today, TempraMed Technologies has over 10 employees. |
| Is TempraMed Technologies publicly listed? | Yes, TempraMed Technologies is a public company listed on Canadian Securities Exchange. |
| What is the stock symbol of TempraMed Technologies? | TempraMed Technologies trades under VIVI ticker. |
| When did TempraMed Technologies go public? | TempraMed Technologies went public in 2025. |
| Who are competitors of TempraMed Technologies? | TempraMed Technologies main competitors include Carelabs, ContextVision, Doctor Care Anywhere, Jin Medical International, Cambridge Cognition, Rockwell Medical, NextPlat, Healixa, CareView Communications, Prolight Diagnostics. |
| What is the current market cap of TempraMed Technologies? | TempraMed Technologies' current market cap is $27M. |
| What is the current revenue of TempraMed Technologies? | TempraMed Technologies' last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of TempraMed Technologies? | Current revenue multiple of TempraMed Technologies is 15.2x. |
| Is TempraMed Technologies profitable? | No, TempraMed Technologies is not profitable. |
| How many companies TempraMed Technologies has acquired to date? | TempraMed Technologies hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies TempraMed Technologies has invested to date? | TempraMed Technologies hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to TempraMed Technologies
Lists including TempraMed Technologies
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




